Search Results
Your search for Staff matches 7010 pages
Showing 1251 - 1300Expert Point of View: Hiroaki Akamatsu, MD, PhD
Abstract discussant Hiroaki Akamatsu, MD, PhD, of Wakayama Medical University, Japan, highlighted the promising efficacy data supporting iruplinalkib, a highly selective, oral inhibitor of ALK and ROS1, in patients with ALK-positive non–small cell lung cancer (NSCLC). “The efficacy profile is very ...
Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC
The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 A...
Expert Point of View: Gerard A. Silvestri, MD, MS
Gerard A. Silvestri, MD, MS, the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina, Charleston, praised the investigators of the Taiwan National Lung Cancer Screening Program for their accomplishment. “It’s incredible that they screened almost 50,000...
Taiwan National Lung Cancer Early Detection Screening Program Targets Smokers and Nonsmokers With Family History
Findings from the Taiwan National Lung Cancer Early Detection Program have shown that lung cancer screening by low-dose computed tomography (CT) can detect tumors at an early-enough phase to allow for effective intervention. In a recent analysis, 85% of tumors detected by screening were stage 0 or...
Expert Point of View: Paula Antonia Ugalde, MD
Discussant of the abstract on the MARS-2 trial, Paula Antonia Ugalde, MD, Associate Surgeon, Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston, underscored the significance of this “outstanding trial,” which she called a “landmark study for the field.” Despite the ban on asbestos, ...
Extended Pleurectomy Decortication Plus Chemotherapy for Mesothelioma Linked to Increased Risk of Death in MARS-2 Trial
The results of a recent study from the United Kingdom could spell the end of a long-standing treatment strategy for mesothelioma, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer.1 When combined with...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 100 members during its annual meeting, including 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated major...
Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023
Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated...
ASCO Applauds Appointment of W. Kimryn Rathmell, MD, PhD, as Next NCI Director
On November 17, President Joe Biden announced the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for Director of the National Cancer Institute (NCI). Dr. ...
Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses new findings on AZD7789, which targets PD-1 and TIM-3, in patients with stage IIIB–IV non–small cell lung cancer (NSCLC) with previous anti–PD-L1 therapy. This bispecific antibody showed manageable safety and preliminary...
FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, the U.S. Food and Drug Administration (FDA) approved the androgen receptor inhibitor enzalutamide (Xtandi) for patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. EMBARK Trial Efficacy was evaluated in EMBARK...
AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in prevention and early detection, has led to a 33% reduction in cancer...
Partial-Breast Irradiation in Patients With Early-Stage Invasive Breast Cancer or DCIS
The American Society for Radiation Oncology (ASTRO) issued recommendations for patient-centered strategies for performing partial-breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The new clinical guidelines were published by Shaitelman et al ...
Updated Findings on Increased Cancer Occurrence in Sweden After 1986 Chernobyl Accident
Researchers have uncovered an increased incidence of certain types of cancer in Sweden following the Chernobyl nuclear power plant accident, according to a novel study published by Tondel et al in Environmental Epidemiology. Study Methods and Results The Chernobyl accident in 1986 led to the spread ...
FDA Approves Capivasertib With Fulvestrant for Breast Cancer
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an...
FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC
On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...
Occupational Exposure to Solar UV Radiation and Nonmelanoma Skin Cancer
Individuals who experience occupational exposure to solar ultraviolet (UV) radiation may have a high rate of nonmelanoma skin cancer incidence and mortality, according to a recent study published by Pega et al in Environment International. These findings highlighted the large and increasing burden...
Number of Cancer Treatments Performed During Early COVID-19 Pandemic
Investigators have uncovered that fewer surgical, chemotherapy, and radiation treatments may have been performed in patients with cancer during the first months of the COVID-19 pandemic, according to a recent study published by Nogueira et al in JAMA Oncology. The new findings may be attributable...
Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine...
Novel Assay May Help Detect and Treat Patients With AML
A novel assay may be effective at detecting a unique molecular marker in patients with acute myeloid leukemia (AML), according to a recent study published by Young et al in The Journal of Molecular Diagnostics. The new findings may revolutionize the way AML is detected and treated. Background AML...
Researchers Identify Novel Genetic Variants Predictive of Prostate Cancer Risk and Severity
Researchers have compiled a comprehensive list of genetic variants that may be associated with the risk of developing prostate cancer, according to a recent study published by Wang et al in Nature Genetics. The new findings included major increases in representation among patients from racial and...
Exposure to CT Radiation and Risk of Blood Cancers in Young Patients
Investigators may have uncovered an association between exposure to computed tomography (CT) radiation in young patients and an increased risk of hematologic malignancies, according to a recent study published by Bosch de Basea Gomez et al in Nature Medicine. These recent findings highlighted the...
Comparing the Accuracy of Initial Staging Methods in Prostate Cancer
Bone scans may overstage prostate cancer at initial staging compared with prostate-specific membrane antigen (PSMA) positron-emission tomography (PET), according to a recent study published by Hope et al in The Journal of Nuclear Medicine. Background PSMA PET is known to be more accurate than...
Cancer Care Disparities Among Patients With Early-Onset Colorectal Cancer
Investigators have found that Black patients with early-onset colorectal cancer in the United States may receive worse and less timely, guideline-concordant care than White patients, according to a recent study published by Nogueira et al in the Journal of Clinical Oncology. Background “Colorectal...
Patients With Lower-Extremity Lymphedema May Face Increased Risk of Skin Cancer
The risk of developing skin cancer may be twofold for patients with lymphedema, according to a recent study published by Anand et al in Mayo Clinic Proceedings. The new findings may contribute to growing information linking lymphedema to localized changes in immunity and a predisposition for...
Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
On November 9, the U.S. Food and Drug Administration (FDA) approved ADAMTS13, recombinant-krhn (Adzynma), the first genetically engineered protein product indicated for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic...
FDA Amends Pembrolizumab’s Gastric Cancer Indication
On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer
On November 8, the U.S. Food and Drug Administration (FDA) approved fruquintinib (Fruzaqla) for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if their disease is RAS wild-type and it...
British Pharmacological Society Names V. Craig Jordan, DSc, PhD, Recipient of the Sir Henry Wellcome Gold Medal
In December 2023, the British Pharmacological Society will present the Sir Henry Wellcome Gold Medal to Prof. V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS. This is the highest award for lifetime contributions to pharmacology by the British Pharmacological Society of Great Britain. Dr. Jordan ...
Genetics of Nearby Healthy Tissue May Help Predict Lung Cancer Recurrence
Genetic information collected from healthy tissue near lung tumors may be predictive of posttreatment cancer recurrence compared with analysis of the tumors themselves, according to a novel study published by Dolgalev et al in Nature Communications. Background Lung adenocarcinomas are tumors that...
Computer Models May Help Reduce Cancer Disparities
Sophisticated computer models may help reduce health disparities in incidence and mortality for patients with major cancer types, according to a collection of new studies published in a special issue of the Journal of the National Cancer Institute. Background Given the high costs and long time...
ASCO Applauds Confirmation of Monica Bertagnolli, MD, FACS, FASCO, as NIH Director
On November 7, the Senate overwhelmingly confirmed Monica M. Bertagnolli, MD, FACS, FASCO, by a vote of 62 to 36, as the 17th Director of the National Institutes of Health (NIH). Dr. Bertagnolli is currently Director of the National Cancer Institute (NCI). She served as ASCO President from 2018 to ...
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data...
Nemtabrutinib May Provide Benefit in Patients With Relapsed Hematologic Malignancies
The BTK inhibitor nemtabrutinib may offer a new treatment option for patients with relapsed hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, according to a recent study published by Woyach et al in Cancer Discovery. Background Hematologic malignancies are...
Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in...
Race, PSA Level, and Risk of Prostate Cancer
Black men in the United States are more likely to develop prostate cancer than White men, and after diagnosis, they’re more likely to have advanced disease and to die of the disease than White men. Although it would seem that earlier prostate‐specific antigen (PSA) screening would reduce the risk...
Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy
Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) (Abstract 1261O).
Can High BMI in Youth Affect Cancer Risk Later On?
Men with overweight or obesity at age 18 years may have a higher risk of 17 different cancers later in life, according to recent research from the University of Gothenburg. The findings also describe how the youth obesity epidemic is expected to affect cancer incidence over the next 30 years. In...
Machine-Learning Model May Accurately Calculate Chemotherapy Success in Patients With Osteosarcoma
Researchers have developed and trained a new machine learning model to calculate percent necrosis in patients with osteosarcoma, according to a novel study published by LiBrizzi et al in the Journal of Orthopaedic Research. Background A postchemotherapy percent necrosis calculation often helps...
Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL
Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...
Secondary PIK3CA Mutations, Drug Resistance, and Novel PI3K Alpha Inhibitors in Breast Cancer
Researchers have discovered that resistance to PI3K-alpha inhibitors and reduced drug binding in patients with breast cancer may be driven by secondary PIK3CA mutations and so may be effectively treated with a novel class of PI3K-alpha inhibitors designed to bind to different parts of the target,...
Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients
Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...
2023 National Youth Tobacco Survey Shows Drop in E-Cigarette Use Among High School Students
On November 2, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released data from the 2023 National Youth Tobacco Survey (NYTS) on tobacco product use among U.S. youth. The findings—which were collected between March and June 2023 and were...
Novel Blood Test May Offer Early Cancer Detection
Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...
Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases
Researchers have explored the impact of immune checkpoint inhibition and single-fraction stereotactic radiosurgery on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases, according to a novel study published by Lehrer et al in the Journal of Neuro-Oncology. Study ...
International Group of Surgical Oncologists Presents New Commission Outlining Pragmatic Solutions to Improve Cancer Surgery Outcomes Worldwide
Building upon recommendations from the 2015 Lancet Oncology Global Cancer Surgery Commission, a new Commission report aims to provide a pragmatic roadmap for decision-makers to reduce inequities and promote safe, timely, and affordable cancer surgery for every patient. The Commission report was...
FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer
On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...
Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase III findings from the SAPPHIRE study of sitravatinib plus nivolumab vs docetaxel in patients with previously treated, advanced nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA63).
